You just read:

Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma

News provided by

Elios Therapeutics, LLC

Jul 17, 2019, 07:30 ET